UKCTAS academic staff
Paul receives a salary from the University of Oxford and the NHS for his work as a GP. His research is funded by public bodies, mostly NIHR. He has undertaken occasional work for pharmaceutical companies on smoking cessation.
Petra is on the scientific advisory board of the Institute of Alcohol Studies. Her research is funded by public funding bodies and medical research charities.
John chairs the Royal College of Physician's Tobacco Advisory Group and is a member of the board of trustees of Action on Smoking and Health
Peter has received research funding from and provided consultancies to manufacturers of smoking cessation medications
Tim has received occasional honoraria for delivering invited lectures (content developed independently) from GlaxoSmithKline and Pierre Fabre Laboratories (PFL) and also for attending symposia organised by PFL and in relation to consultancy work for Pfizer. All of these companies either manufacture or have manufactured smoking cessation treatments.
Matt Field’s academic salary is provided by the University of Liverpool, through HEFCE funding. He has received research and travel funding from Research Councils (Medical Research Council and the Economic and Social Research Council) other funders (British Academy, Royal Society) and charities (Wellcome Trust, Alcohol Research UK). He has received consulting fees from Blink Media for media work. He has received honoraria for training workshops and invited lectures from Universities (University of Reading) and professional organisations (e.g. British Psychological Society Division of Clinical Psychology; British Association for Behavioural and Cognitive Therapists). He has no equity holdings in pharmaceutical, tobacco or alcohol companies aside from possible inclusion in mutual funds over which he has no control as an individual investor.
Funding: Anna Gilmore’s research has recently been funded by the National Cancer Institute, US National Institutes of Health (NIH), Cancer Research UK, the Medical Research Council and the Economic and Social Research Council. Previous major funders include the European Commission Seventh Framework Programme (FP7), the Health Foundation and the Wellcome Trust. Additional funding has been provided by NHS South West, later Smokefree South West and the Canadian Institutes of Health (CIHR).
She has received consulting fees from the Bloomberg Global Initiative, the American Cancer Society, The Polish Health Promotion Foundation, RAND Europe, Smokefree NorthWest and the European Commission.
Unpaid advisory work (travel expenses occasionally reimbursed): Member of the Council of Action on Smoking and Health (ASH); Member of the WHO Expert Committee, which addressed tobacco industry interference with tobacco control policy; Member of the Royal College of Physicians, Tobacco Advisory Group; Friend of ASH Wales; Member of the Cancer Research UK/BUPA Foundation Cancer Prevention Initiative International Advisory Board; Member of Smokefree South West Programme Board. Potential conflicts of interest: AG has no equity holdings in and has never taken research funds from pharmaceutical, tobacco or alcohol companies.
Marcus’ academic salary is provided by the University of Bristol, through HEFCE funding.
He has received research funding from the National Health Service and various research councils and charities, which have included the Alcohol Education and Research Council, the European Research Advisory Board and Pfizer. In addition, he has received nicotine replacement products from GlaxoSmithKline and Pfizer for distribution to study participants. He has received consulting fees from the American Institutes for Research, the European Commission, the National Audit Office, Servier and the World Health Organisation.
He has received honoraria for invited lectures from GlaxoSmithKline, Novartis and Sepracor, and from various academic institutions, as well as honoraria for editorial activities for Addiction, Nicotine and Tobacco Research and Drug and Alcohol Dependence. He receives royalties from academic books he has published, and through the Authors’ Licensing and Collecting Society. He is listed as a co-inventor on a patent for the use of carbon-dioxide enriched air in the treatment of addiction. He is a director of Jericoe Ltd, which develops software for assessing and modifying emotion perception. He has no equity holdings in pharmaceutical, tobacco or alcohol companies aside from possible inclusion in mutual funds over which he has no control as an individual investor.
Linda Bauld, Richard Ashcroft, Graeme Docherty, Chris Griffin, Chris Hill, Jo Leonardi-Bee, Susan Michie: No conflicting interests